Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure

Gynecologic Oncology

Volumn 92, Issue 2, 2004, Pages 596-602

  Farley, John ^a   Uyehara, Catherine ^a   Hashiro, Glenn ^a   Belnap, Christina ^a   Birrer, Michael ^b   Salminen, Eric ^a  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cervical dysplasia; Cyclooxygenase 2; LEEP

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN P27;

ARTICLE; CHI SQUARE DISTRIBUTION; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; DISEASE SEVERITY; ELECTROSURGERY; FEMALE; FISHER EXACT TEST; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELL; TUMOR RECURRENCE; UTERINE CERVIX DYSPLASIA;

EID: 0842288955     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.10.052     Document Type: Article

References (47)

1. Becker T.M., Stone K.M., Alexander E.R. Genital human papillomavirus infection. A growing concern. Obstet. Gynecol. Clin. North Am. 14:1987;389-396.
2. Reid R., Campion M.J. The biology and significance of human papillomavirus infections in the genital tract. Yale J. Biol. Med. 61:1988;307-325.
3. Jones M.H. The management of the mildly dyskaryotic smear. Br. J. Obstet. Gynaecol. 101:1994;474-476.
4. Kurman R.J., Henson D.E., Herbst A.L., Noller K.L., Schiffman M.H. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA. 271:1994;1866-1869.
5. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2003. CA Cancer J. Clin. 52:2002;23-47.
6. van Muyden R.C., ter Harmsel B.W., Smedts F.M., Hermans J., Kuijpers J.C., Raikhlin N.T.et al. Detection and typing of human papillomavirus in cervical carcinomas in Russian women: a prognostic study. Cancer. 85:1999;2011-2016.
7. Slagle B.L., Kaufman R.H., Reeves W.C., Icenogle J.P. Expression of ras, c-myc, and p53 proteins in cervical intraepithelial neoplasia. Cancer. 83:1998;1401-1418.
8. Kersemaekers A.M., Fleuren G.J., Kenter G.G., Van den Broek L.J., Uljee S.M., Hermans J.et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin. Cancer Res. 5:1999;577-586.
9. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338:1998;423-428.
10. Hopman E.H., Rozendaal L., Voorhorst F.J., Walboomers J.M., Kenemans P., Helmerhorst T.J. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG. 107:2000;600-604.
11. Laukkanen P, Koskela P, Pukkala E, Dillner J, Laara E, Knekt P, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J. Cell Physiol. 2003;84(Pt 8):2105-9, 0022-1317.
12. Chesebro M.J., Everett W.D. A cost-benefit analysis of colposcopy for cervical squamous intraepithelial lesions found on Papanicolaou smear. Arch. Fam. Med. 5:1996;576-581.
13. Shamma A., Yamamoto H., Doki Y., Okami J., Kondo M., Fujiwara Y.et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res. 6:2000;1229-1238.
14. Lim H.Y., Joo H.J., Choi J.H., Yi J.W., Yang M.S., Cho D.Y.et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin. Cancer Res. 6:2000;519-525.
15. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
16. Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. 90:1998;455-460.
17. Ryu H.S., Chang K.H., Yang H.W., Kim M.S., Kwon H.C., Oh K.S. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol. Oncol. 76:2000;320-325.
18. Ishiko O., Sumi T., Yoshida H., Tokuyama O., Wakasa K., Haba T.et al. Cyclooxygenase-2 expression in an adenoid cystic carcinoma of the uterine cervix. Oncol. Rep. 8:2001;1023-1025.
19. Kulkarni S., Rader J.S., Zhang F., Liapis H., Koki A.T., Masferrer J.L. et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7:2001;429-434.
20. Ferrandina G., Lauriola L., Distefano M.G., Zannoni G.F., Gessi M., Legge F.et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J. Clin. Oncol. 20:2002;973-981.
21. Gaffney D.K., Holden J., Davis M., Zempolich K., Murphy K.J., Dodson M. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 49:2001;1213-1217.
22. Gaffney D.K., Holden J., Zempolich K., Murphy K.J., Dicker A.P., Dodson M. Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control. Am. J. Clin. Oncol. 24:2001;443-446.
23. Shiozawa T., Shiohara S., Kanai M., Konishi I., Fujii S., Nikaido T. Expression of the cell cycle regulator p27(Kip1) in normal squamous epithelium, cervical intraepithelial neoplasia, and invasive squamous cell carcinoma of the uterine cervix. Immunohistochemistry and functional aspects of p27(Kip1). Cancer. 92:2001;3005-3011.
24. Farley J., Gray K., Nycum L., Prentice M., Birrer M.J., Jakowlew S.B. Endocervical cancer is associated with an increase in the ligands and receptors for transforming growth factor-beta and a contrasting decrease in p27(Kip1). Gynecol. Oncol. 78:2000;113-122.
25. Fredersdorf S., Burns J., Milne A.M., Packham G., Fallis L., Gillett C.E.et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. U. S. A. 94:1997;6380-6385.
26. Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J. Gen. Viro. 2003;195(1):139-50 [0021-9541].
27. Kudo Y., Kitajjma S., Sato S., Miyauchi M., Ogawa I., Takata T. Establishment of an oral squamous cell carcinoma cell line with high invasive and p27 degradation activities from a lymph node metastasis. Oral. 39(5):2003;515-520. [1368-8375].
28. Goff B.A., Sallin J., Garcia R., VanBlaricom A., Paley P.J., Muntz H.G. Evaluation of p27 in preinvasive and invasive malignancies of the cervix. Gynecology. 88(1):2003;40-44. [0090-8258].
29. Huang L.W., Chao S.L., Hwang J.L., Chou Y.Y. Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecology. 85(3):2002;524-548. [0090-8258].
30. Zahner G., Wolf G., Ayoub M., Reinking R., Panzer U., Shankland S.J.et al. Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor-induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1. J. Biol. Chem. 277:2002;9763-9771.
31. Lloyd R.V., Jin L., Qian X., Kulig E. Aberrant p27kip1 expression in endocrine and other tumors. Am. J. Pathol. 150:1997;401-407.
32. McCarty K.S. Jr., Szabo E., Flowers J.L., Cox E.B., Leight G.S., Miller L.et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 46:1986;4244s-4248s.
33. Saukkonen K., Nieminen O., van Rees B., Vilkki S., Harkonen M., Juhola M.et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin. Cancer Res. 7:2001;1923-1931.
34. Hung W.C., Chang H.C., Pan M.R., Lee T.H., Chuang L.Y. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol. Pharmacol. 58:2000;1398-1403.
35. Teruyama K., Abe M., Nakano T., Iwasaka-Yagi C., Takahashi S., Yamada S.et al. Role of transcription factor Ets-1 in the apoptosis of human vascular endothelial cells. J. Cell. Physiol. 188:2001;243-252.
36. Dong Y.L., Gangula P.R., Fang L., Yallampalli C. Differential expression of cyclooxygenase-1 and-2 proteins in rat uterus and cervix during the estrous cycle, pregnancy, labor and in myometrial cells. Prostaglandins. 52:1996;13-34.
37. Oka K., Suzuki Y., Nakano T. Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognosis. Cancer. 88:2000;2766-2773.
38. Troncone G., Vetrani A., de Rosa G., Gerbasio D., Palombini L. Cyclin dependent kinase inhibitor p27Kip1 expression in normal and neoplastic cervical epithelium. J. Clin. Pathol. 52:1999;880-887.
39. Farley J., Smith L.M., Darcy K.M., Sobel E., O'Connor D., Henderson B.et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a gynecologic oncology group study. Cancer Res. 63:2003;1235-1241. [Corporate name: Gynecologic Oncology Group].
40. Mitchell M.F., Tortolero-Luna G., Wright T., Sarkar A., Richards-Kortum R., Hong W.K.et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J. Natl. Cancer Inst. Monogr. 1996;17-25.
41. Barron B.A., Richart R.M. A statistical model of the natural history of cervical carcinoma based on a prospective study of 557 cases. J. Natl. Cancer Inst. 41:1968;1343-1353.
42. Luesley D.M., Cullimore J., Redman C.W., Lawton F.G., Emens J.M., Rollason T.P.et al. Loop diathermy excision of the cervical transformation zone in patients with abnormal cervical smears. BMJ. 300:1990;1690-1693.
43. Kolstad P., Klem V. Long-term follow-up of 1121 cases of carcinoma in situ. Obstet. Gynecol. 48:1976;125-129.
44. Dietrich C.S. III, Yancey M.K., Miyazawa K., Williams D.L., Farley J. Risk factors for early cytologic abnormalities after loop electrosurgical excision procedure. Obstet. Gynecol. 99:2002;88-92.
45. Baldauf J.J., Dreyfus M., Ritter J., Cuenin C., Tissier I., Meyer P. Cytology and colposcopy after loop electrosurgical excision: implications for follow-up. Obstet. Gynecol. 92:1998;124-130.
46. Murdoch J.B., Morgan P.R., Lopes A., Monaghan J.M. Histological incomplete excision of CIN after large loop excision of the transformation zone (LLETZ) merits careful follow up, not retreatment. Br. J. Obstet. Gynaecol. 99:1992;990-993.
47. Costa S., De Nuzzo M., Infante F.E., Bonavita B., Marinelli M., Rubino A.et al. Disease persistence in patients with cervical intraepithelial neoplasia undergoing electrosurgical conization. Gynecol. Oncol. 85:2002;11-124.